BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Events//NONSGML v1.0//EN
METHOD:PUBLISH
BEGIN:VEVENT
DTSTART;TZID="Pacific Time (US & Canada)":20260303T123000
DTEND;TZID="Pacific Time (US & Canada)":20260303T133000
SUMMARY:Organic Seminar – Oscar Hernandez
LOCATION:Fulmer Hall
DESCRIPTION:Organic Seminar, 3/3/2026, 12:30 PM, Fulmer 438\n\nSpeaker: Oscar Hernandez\n\nGroup: Dr. Cliff Berkman\n\nTitle: A HER2-targeting antibody-MMAE conjugate RC48 sensitizes immunotherapy in HER2-positive colon cancer by triggering the cGAS-STING pathway\n\nAbstract\n\nThis presentation will focus on the work conducted by Dr. Xiaohan Wu’s group which focuses on targeted drug therapy for HER2 expressing colon cancer. Human epidermal growth factor receptor 2 (HER2) is a protein that is overexpressed in some types of cancer, including breast and urothelial cancer. Herein Dr. Wu’s group found that HER2 was present in a portion of colon cancer patients, raising the possibility of using anti-HER2 therapy. RC48, a novel antibody-drug conjugate (ADC) comprising cytotoxic monomethyl auristatin E (MMAE) and an anti-HER2 antibody tethered via a linker, showed a comparable therapeutic effect in both HER2 low expressed (IHC2+/FISH- or IHC+) and high expressed urothelial cancer patients. In vitro studies using colon cancer cell lines showed that RC48 effectively impeded the proliferation of HER2-positive cells, indicating its potential as a treatment for HER2-positive colon cancer. Mechanism study showed that RC48 not only induces cell cycle arrest but also disrupts HER2-mediated restain of cGAS-STING signaling, potentially activating an immune response against the cancer cells. The administration of RC48 significantly reduced the growth of HER2- positive colon cancer and made HER2-positive colon cancer cells more susceptible to immunotherapy. The results of this study will contribute to determining the feasibility of RC48 as a therapeutic option for HER2-positive colon cancer.\n\nReferences\n\nWu X, Xu L, Li X, Zhou Y, Han X, Zhang W, Wang W, Guo W, Liu W, Xu Q, Gu Y. A HER2-targeting antibody-MMAE conjugate RC48 sensitizes immunotherapy in HER2-positive colon cancer by triggering the cGAS-STING pathway. Cell Death Dis. 2023 Aug 24;14(8):550. doi: 10.1038/s41419-023-06073-8. PMID: 37620320; PMCID: PMC10449775.
BEGIN:VALARM
ACTION:DISPLAY
DESCRIPTION:REMINDER
TRIGGER;RELATED=START:-PT00H15M00S
END:VALARM
END:VEVENT
END:VCALENDAR